Abstract: The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions.

Abstract: The present disclosure describes a PTPN2/PTP1B degrader compounds having the structure of Formula (I), that are useful for treating PTPN2/PTP1B-mediated disorders or conditions,

Abstract: The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions,

Abstract: In some examples, a display device includes a panel, a scaler circuit, and a backlight control circuit. In some examples, the scaler circuit receives a panel identification from the panel and determines a backlight module driving configuration based on the panel identification. In some examples, the backlight control circuit receives the backlight module driving configuration from the scaler circuit and controls a backlight for the panel based on the backlight module driving configuration.

Abstract: The disclosed technology relates to methods, voice enhancement systems, and non- transitory computer readable media for real-time voice enhancement. In some examples, input audio data including foreground speech content, non-content elements, and speech characteristics is fragmented into input speech frames. The input speech frames are converted to low-dimensional representations of the input speech frames. One or more of the fragmentation or the conversion is based on an application of a first trained neural network to the input audio data. The low-dimensional representations of the input speech frames omit one or more of the non-content elements. A second trained neural network is applied to the low-dimensional representations of the input speech frames to generate target speech frames. The target speech frames are combined to generate output audio data. The output audio data further includes one or more portions of the foreground speech content and one or more of the speech characteristics.

Abstract: A pharmaceutical composition comprises, in weight parts, the following components: (a) 1 part compound as shown in formula (I) (b) 0.2 to 15 parts polyvinylpyrrolidone; and (c) 1 part to 25 parts other pharmaceutically acceptable excipients. This pharmaceutical composition can be used for the treatment of steatohepatitis.

Abstract: The present application describes compounds of IL-17A modulator that are useful for treating an IL-17A mediated inflammatory syndrome, disorder, or disease.

Abstract: Certain antiviral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Abstract: In view of the need for a conversational recommender system (CRS) in guiding purchasing processes of complex items, embodiments described herein provide a CRS system that creates a realistic purchase scenario and agent evaluation for fulfilling the recommendation objective. Specifically, the CRS system utilizes existing buying guides as a knowledge source for the recommendation model.

Abstract: Embodiments described herein provide a training framework for generative NLP models. Specifically, the training input, e.g., in the form of a sequence of tokens representing a user-agent dialogue, may be randomly masked for a few spans, which can be one or more tokens, one or more words, one or more sentences, or one or more paragraphs. These masked spans are replaced with their embeddings generated from pre-trained large language models are then used for training the NLP model.

Abstract: Embodiments described herein provide a training framework for generative NLP models that operate on previously learnt knowledge from pretrained large language models. Specifically, to train an NLP model to generate a response to a user utterance (e.g., “resolve login issue”), document embeddings of support IT documents encoded by a pretrained LLM are fed to an NLP decoder together with a training dialogue (e.g., a dialogue between the chat agent on how to “resolve login issue”). The NLP decoder can thus be trained by a causal language modeling loss computed based on the predicted next token and the ground-truth token from the training dialogue.

Abstract: The disclosed technology relates to methods, voice enhancement systems, and non-transitory computer readable media for real-time voice enhancement. In some examples, input audio data including foreground speech content, non-content elements, and speech characteristics is fragmented into input speech frames. The input speech frames are converted to low-dimensional representations of the input speech frames. One or more of the fragmentation or the conversion is based on an application of a first trained neural network to the input audio data. The low-dimensional representations of the input speech frames omit one or more of the non-content elements. A second trained neural network is applied to the low-dimensional representations of the input speech frames to generate target speech frames. The target speech frames are combined to generate output audio data. The output audio data further includes one or more portions of the foreground speech content and one or more of the speech characteristics.

Abstract: A catalytic converter system having oxygen storage materials is disclosed and methods for determining whether to reactivate oxygen storage materials and monitoring failure events of the oxygen storage materials are also disclosed.

Abstract: The present application describes compounds of capsid inhibitors that are useful for treating HIV infection in a human. One aspect of the present application relates to a compound of Formula I, stereoisomers thereof, pharmaceutically acceptable salts thereof, or deuterium substitutes thereof as described in the present disclosure.

Abstract: A pharmaceutical composition comprising: a compound of formula (I) formulated for storage at room temperature and at least one additional therapeutic agent.

Abstract: A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Abstract: The present application describes a thyroid hormone receptor ? subtype agonist derivative, a preparation method and a use thereof.

Abstract: A pharmaceutical composition comprising: a form of compound of formula (I) and at least one additional therapeutic agent, and optionally one or more pharmaceutically acceptable carriers.

Abstract: Disclosed are a compound of Formula I, stereoisomers, pharmaceutically acceptable salts and deuterated compounds thereof and a method for treating, inhibiting and/or preventing a disease or disorder in a subject in need thereof: wherein A, R, G, Y and n are defined as in the present disclosure.

Abstract: A pharmaceutical composition comprising: a compound of formula (1) and a polymer material, wherein the compound of formula (1) maintains a supersaturated concentration in the pharmaceutical composition and is suitable for storage at room temperature.